Surgical repair of rhegmatogenous retinal detachment is currently successful in over 90% of cases.'-4 Where there is a final failure to reattach the retina this is due to the development of proliferative vitreoretinopathy (PVR) in over 75% of cases.5-7 This process is characterised by cellular proliferation on both surfaces of the detached neuroretina, on the posterior vitreous face, and within the vitreous base resulting in the formation of contractile periretinal membranes. It is estimated to occur in 5-10% of all rhegmatogenous retinal detachments.7
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Surgical repair of rhegmatogenous retinal detachment is currently successful in over 90% of cases.'-4 Where there is a final failure to reattach the retina this is due to the development of proliferative vitreoretinopathy (PVR) in over 75% of cases.5-7 This process is characterised by cellular proliferation on both surfaces of the detached neuroretina, on the posterior vitreous face, and within the vitreous base resulting in the formation of contractile periretinal membranes. It is estimated to occur in 5-10% of all rhegmatogenous retinal detachments. 7 Initial clinical observations emphasised cellular activity in, and retraction of, the vitreous together with the appearance of retinal folds. The condition was referred to as massive vitreous retraction (MVR) or massive preretinal retraction (MPR) on the premise of the primary pathology being centred in the vitreous gel.8 This was later modified to massive periretinal proliferation (MPP)9 to acknowledge the role of periretinal membrane formation.
A unifying classification was published by the Retina Society Terminology Committee in 1983.7 This used the term proliferative vitreoretinopathy and has served as the basis for subsequent clinical and laboratory studies. It subdivides PVR into four stages (A-D) of increasing severity based on clinical features: vitreous haze and pigment, retinal stiffness and wrinkling, rolled edges of retinal breaks, vascular tortuosity, and fixed retinal folds advancing to a funnel retinal detachment. A revised form of this classification further subdivides the proliferative process by location (anterior/posterior) and type (focal/diffuse/subretinal/circumferential and anterior displacement).' 0 While these classifications have served to standardise the terminology and clinical descriptions used in dealing with PVR they are essentially anatomical and do not address the biological activity of the PVR process. Furthermore, they do not record clinically important information such as the number, size, and location of retinal breaks, factors known to be of significance in the risk of development and progression of PVR." The existing classifications therefore have limitations with respect to the comparison of the biological stage and the level of activity ofthe process between individual eyes in clinical or laboratory studies.
Pathophysiology CELLULAR CONSTITUENTS
PVR can be viewed as a wound healing process in a specialised tissue. Various studies have addressed the question of the cellular composition of the periretinal membranes which are the central feature of the pathobiology. There is general agreement that four categories of cell can be identified (Table 1) .
Retinal pigment epithelial (RPE) cells have been identified by light and electron microscopy'2-'4 and immunohistochemically. '5-17 Based on the finding of fibroblastic cells, some of which have been demonstrated to contain cytoplasmic myofilaments,'3 15 33 it has been proposed that membrane shortening is mediated by intrinsic contraction of these component cells, thus producing the tractional forces found clinically in PVR. An in vitro system has shown that both RPE and fibroblasts, but not retinal glia, are capable of mediating the contraction of a type I collagen matrix by cellular mobility and subsequent attachment of collagen fibres. 5' Experimental work has suggested an alternative mechanism of membrane contraction involving the interaction of RPE cells and collagen.52 In this scheme collagen fibres are pulled by the RPE cells by alternating extension and retraction of their lamellipodia (fibronectin serving as a bridge between RPE and collagen), collagen is piled up adjacent to the RPE cell with subsequent tissue shortening.
The role of growth factors/cytokines Recent studies on the pathogenesis of PVR have investigated the mediators of the cellular events outlined above. Growth factors have the potential to regulate the chemotaxis, proliferation, contraction, and extracellular matrix elaboration by the cells involved in PVR and hence are likely to be centrally involved in its pathobiology. Results of growth factor/cytokine studies are summarised in Table 3 .
In vitro experimental work has demonstrated that RPE cells can respond by mitogenesis and chemotaxis to vitreous derived fluid obtained after blood-retinal barrier T lymphocytes and macrophages are fundamental cellular components ofnormal wound healing82 83 and have been shown to have a reciprocal interaction via growth factors in the wound healing process.8485 Moreover, it has been shown that fibroblasts may produce a soluble factor which can prolong T cell survival86 and hence potentiate the role of T cells at foci of fibrogenesis. The presence of cells involved in the immune response does not therefore imply an autoimmune mechanism as part of the pathogenesis of PVR. None the less, lymphocytes and macrophages have the potential to play a significant role in the development of PVR; mediating the pathobiology through growth factor secretion and the subsequent regulation of cellular chemotaxis and proliferation and the production of collagen, fibronectin, and other extracellular matrix components. [87] [88] [89] [90] [91] Surgical management of PVR The basic principles of the surgical treatment of retinal detachments complicated by PVR are those of detachment surgery in general -that is, the closure and sealing of retinal breaks and the complete release of periretinal traction. To these can be added the prevention of recurrence of the proliferative process and its ensuing tractional forces.
Retinal detachments in eyes with only minimal PVR may be treated successfully by an external scleral buckling procedure. 92 However, expansile gas should be used with caution in such cases since there is evidence to suggest that this may increase the incidence and progression of PVR.9395
Successful surgical reattachment ofrecurrent retinal detachments in the absence of advanced PVR can be achieved by modification of the scleral buckle in selected cases. 96 In general, vitrectomy techniques are the basis of surgery for moderate to advanced PVR. Microsurgical manipulation allows the dissection and removal of epiretinal (and occasionally subretinal) membranes, thereby relieving tractional forces on the retina and permitting reattachment. Since cryotherapy is known to promote the dispersion of viable RPE cells and hence the progression of PVR.20 21 when possible laser photocoagulation is favoured to produce a chorioretinal adhesion around retinal breaks.
In eyes where there is advanced PVR, anterior proliferation in the region of the vitreous base and around the preequatorial retina is often a prominent feature.10 Lewis The effect of intraocular tamponade on the proliferative process is as yet uncertain. Studies on the use of silicone oil after vitrectomy in eyes with PVR have reported a high rate of retro-oil epiretinal membrane reproliferation,108 particularly in association with large retinectomies.102 109 Histopathological study of the membranes formed has shown silicone oil droplets within membrane extracellular matrix'09 110 which persists after oil removal. Potentially, silicone oil could downregulate membrane formation by limiting access of cells and growth factors to the retinal surface or may produce upregulation by compartmentalising these in contact with the retina. Experimental animal work has shown that silicone oil does not prevent epiretinal membrane formation.I L1-13 Moreover, one study has documented an increased incidence of membrane formation and tractional retinal detachment in oil filled compared with perfluoropropane or fluid filled eyes" 4 with a corresponding increased RPE mitogenic effect of silicone oil associated vitreous cavity fluid. Growth factor regulators 150 The clinical significance of the reproliferative effect of silicone oil remains unresolved although the results of the Silicone Study Group'06 would suggest that oil and perfluoropropane gas do not greatly differ in their potential to produce reproliferation and subsequent surgical failure.
As vitreoretinal surgical techniques have advanced the anatomical success rate of retinal surgery in severe PVR has increased from around 60% to over 900/0 in recently reported series.98 99 115 Visual results, however, are often disappointing and the value of such surgery has been questioned. Analysis of the results of PVR surgery has shown that unilaterally aphakic eyes seldom achieve beneficial vision following complex PVR surgery and that subjective visual comfort is often poor owing to diplopia and photophobia."6 Despite this most patients report that surgery was worthwhile. 116 117 Adjunctive treatment Studies on the pathobiology of PVR have identified the elements involved -fibrin deposition, cellular accumulation and proliferation, production of extracellular matrix, and contraction of the membranes formed. It has become possible to design pharmacological adjuncts to the surgical management of the condition which specifically target the cellular components and pathological processes of PVR (Table 4) .
NON-SPECIFIC ANTIPROLIFERATIVE AGENTS
The proliferation of the cellular subtypes (RPE, glia, fibroblastic cells, and inflammatory cells) is a key stage in the progression of PVR. Various pharmacological agents are available which will inhibit the proliferation of the cells involved in PVR either through a general antiproliferative effect or via inhibition of a specific cellular type.
The antiproliferative agent 5-fluorouracil (5-FU) has been shown to be effective in reducing the incidence of PVR in animal models"8 119 and appears to be relatively non-toxic at the levels required to be effective in experimental eyes."8 120 A prospective study in human eyes using a single intravitreal injection of a high dose of 5-FU (10 mg) at the completion of vitrectomy for PVR12' demonstrated that this dosage was well tolerated, a result also found in a previous study using 1 mg of intravitreal 5-FU122; however, surgical success was not improved in the treated groups.
The efficacy of other antiproliferative agents in PVR has also been investigated. Daunorubicin (daunomycin) has been tested both experimentally and clinically. In an experimental animal model of PVR daunomycin prevented retinal detachment if injected at the time of PVR induction or in two doses 3 days later.'23 Uncontrolled clinical studies have been carried out using an infusion of daunomycin 7-5 mg/l for 10 minutes at the time of vitrectomy surgery on PVR following both trauma and rhegmatogenous retinal detachment.' 24 125 Results indicate that this dosage appears to be well tolerated and produced surgical success rates which the authors felt improved on their previous work. A multicentre European trial is currently being conducted to investigate the potential role of daunomycin as an adjunct in PVR management. 126 The ocular toxicity of a range of antiproliferative agents has been investigated experimentallyl27; however, data on the clinical efficacy and safety of the majority of antiproliferative drugs are limited at present. Ocular irradiation has been proposed as a potential therapeutic option in the treatment of PVR. In vitro studies have shown that low dose irradiation can markedly inhibit RPE cell division'28 and animal work has demonstrated that low dose irradiation given early or late in the proliferative process can reduce the incidence of tractional retinal detachment. ' 
